The in Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD is Mediated by Tumor-specific Immunity

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 May 29

PMID 24866126

Citations 43

Authors

Anne Kleijn

Jenneke Kloezeman

Elike Treffers-Westerlaken

Giulia Fulci

Sieger Leenstra

Clemens Dirven

Reno Debets

Martine Lamfers

Affiliations

Soon will be listed here.

Abstract

The oncolytic adenovirus Delta24-RGD represents a new promising therapeutic agent for patients with a malignant glioma and is currently under investigation in clinical phase I/II trials. Earlier preclinical studies showed that Delta24-RGD is able to effectively lyse tumor cells, yielding promising results in various immune-deficient glioma models. However, the role of the immune response in oncolytic adenovirus therapy for glioma has never been explored. To this end, we assessed Delta24-RGD treatment in an immune-competent orthotopic mouse model for glioma and evaluated immune responses against tumor and virus. Delta24-RGD treatment led to long-term survival in 50% of mice and this effect was completely lost upon administration of the immunosuppressive agent dexamethasone. Delta24-RGD enhanced intra-tumoral infiltration of F4/80+ macrophages, CD4+ and CD8+ T-cells, and increased the local production of pro-inflammatory cytokines and chemokines. In treated mice, T cell responses were directed to the virus as well as to the tumor cells, which was reflected in the presence of protective immunological memory in mice that underwent tumor rechallenge. Together, these data provide evidence that the immune system plays a vital role in the therapeutic efficacy of oncolytic adenovirus therapy of glioma, and may provide angles to future improvements on Delta24-RGD therapy.

Citing Articles

Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy.

Lecoultre M, Walker P, El Helali A Clin Exp Med. 2024; 24(1):202.

PMID: 39196415 PMC: 11358230. DOI: 10.1007/s10238-024-01443-8.

Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment.

Zhang L, Pakmehr S, Shahhosseini R, Hariri M, Fakhrioliaei A, Shayan F Med Oncol. 2023; 41(1):8.

PMID: 38062315 DOI: 10.1007/s12032-023-02233-0.

Convection-enhanced delivery of immunomodulatory therapy for high-grade glioma.

Sperring C, Argenziano M, Savage W, Teasley D, Upadhyayula P, Winans N Neurooncol Adv. 2023; 5(1):vdad044.

PMID: 37215957 PMC: 10195574. DOI: 10.1093/noajnl/vdad044.

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.

Nassiri F, Patil V, Yefet L, Singh O, Liu J, Dang R Nat Med. 2023; 29(6):1370-1378.

PMID: 37188783 PMC: 10287560. DOI: 10.1038/s41591-023-02347-y.

Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy.

Omole R, Oluwatola O, Akere M, Eniafe J, Agboluaje E, Daramola O Front Pharmacol. 2022; 13:1082797.

PMID: 36569326 PMC: 9772532. DOI: 10.3389/fphar.2022.1082797.

References

Blackham A, Northrup S, Willingham M, DAgostino Jr R, Lyles D, Stewart 4th J . Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus. Surgery. 2012; 153(3):333-43. PMC: 3561511. DOI: 10.1016/j.surg.2012.09.003. View

Robbins P, Morgan R, Feldman S, Yang J, Sherry R, Dudley M . Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011; 29(7):917-24. PMC: 3068063. DOI: 10.1200/JCO.2010.32.2537. View

Kiang A, Hartman Z, Everett R, Serra D, Jiang H, Frank M . Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system. Mol Ther. 2006; 14(4):588-98. DOI: 10.1016/j.ymthe.2006.03.024. View

Badie B, Schartner J, Paul J, Bartley B, Vorpahl J, Preston J . Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study. J Neurosurg. 2000; 93(4):634-9. DOI: 10.3171/jns.2000.93.4.0634. View

Lamfers M, Grill J, Dirven C, van Beusechem V, Geoerger B, van den Berg J . Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res. 2002; 62(20):5736-42. View

Alvarez-Breckenridge C, Yu J, Price R, Wojton J, Pradarelli J, Mao H . NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med. 2012; 18(12):1827-34. PMC: 3668784. DOI: 10.1038/nm.3013. View

Thomas M, Spencer J, Toth K, Sagartz J, Phillips N, Wold W . Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol Ther. 2008; 16(10):1665-73. PMC: 3437752. DOI: 10.1038/mt.2008.162. View

Rolle C, Sengupta S, Lesniak M . Mechanisms of immune evasion by gliomas. Adv Exp Med Biol. 2012; 746:53-76. DOI: 10.1007/978-1-4614-3146-6_5. View

Galanis E, Okuno S, Nascimento A, Lewis B, Lee R, Oliveira A . Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther. 2005; 12(5):437-45. DOI: 10.1038/sj.gt.3302436. View

10.

Young A, Archibald K, Tookman L, Pool A, Dudek K, Jones C . Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo. Mol Ther. 2012; 20(9):1676-1688. PMC: 3437579. DOI: 10.1038/mt.2012.116. View

11.

Wherry E . T cell exhaustion. Nat Immunol. 2011; 12(6):492-9. DOI: 10.1038/ni.2035. View

12.

Chiocca E, Abbed K, Tatter S, Louis D, Hochberg F, Barker F . A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther. 2004; 10(5):958-66. DOI: 10.1016/j.ymthe.2004.07.021. View

13.

Freeman A, Zakay-Rones Z, Gomori J, Linetsky E, Rasooly L, Greenbaum E . Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther. 2005; 13(1):221-8. DOI: 10.1016/j.ymthe.2005.08.016. View

14.

Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I . Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res. 2013; 19(10):2734-44. DOI: 10.1158/1078-0432.CCR-12-2546. View

15.

Idema S, Lamfers M, van Beusechem V, Noske D, Heukelom S, Moeniralm S . AdDelta24 and the p53-expressing variant AdDelta24-p53 achieve potent anti-tumor activity in glioma when combined with radiotherapy. J Gene Med. 2007; 9(12):1046-56. DOI: 10.1002/jgm.1113. View

16.

Markert J, Medlock M, Rabkin S, Gillespie G, Todo T, Hunter W . Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000; 7(10):867-74. DOI: 10.1038/sj.gt.3301205. View

17.

Bauerschmitz G, Kanerva A, Wang M, Herrmann I, Shaw D, Strong T . Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer. Int J Cancer. 2004; 111(2):303-9. DOI: 10.1002/ijc.20217. View

18.

Sprangers M, Lakhai W, Koudstaal W, Verhoeven M, Koel B, Vogels R . Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol. 2003; 41(11):5046-52. PMC: 262545. DOI: 10.1128/JCM.41.11.5046-5052.2003. View

19.

Lesniak M, Gabikian P, Tyler B, Pardoll D, Brem H . Dexamethasone mediated inhibition of local IL-2 immunotherapy is dose dependent in experimental brain tumors. J Neurooncol. 2004; 70(1):23-8. DOI: 10.1023/b:neon.0000040821.50347.c5. View

20.

Sebestyen Z, de Vrij J, Magnusson M, Debets R, Willemsen R . An oncolytic adenovirus redirected with a tumor-specific T-cell receptor. Cancer Res. 2007; 67(23):11309-16. DOI: 10.1158/0008-5472.CAN-07-0739. View